Discovery of an M -Substituted N -Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active κ-Opioid Receptor Agonist with an Improved Central Nervous System Safety Profile

Qian He,Yuanyuan Wei,Xiao Liu,Rongrong Ye,Linghui Kong,Zixiang Li,Shuang Jiang,Linqian Yu,Jingrui Chai,Qiong Xie,Wei Fu,Yujun Wang,Wei Li,Zhuibai Qiu,Jinggen Liu,Liming Shao

DOI: https://doi.org/10.1021/acs.jmedchem.1c01082

IF: 8.039

2021-08-13

Journal of Medicinal Chemistry

Abstract:The search for selective kappa opioid receptor (κOR) agonists with an improved safety profile is an area of interest in opioid research. In this work, a series of m-substituted analogs were designed, synthesized, and assayed, resulting in the identification of compound 6c (SLL-1206) as a κOR agonist with single-digit nanomolar activities. The subtype selectivity of compound 6c appeared to be a consequence of an enormous decrease in the affinity for μOR and δOR, rather than a significant increase in the affinity for κOR, which was not the case for SLL-039, another selective and potent κOR agonist identified in our previous work. Besides reduced central nervous system effects, SLL-1206 exhibited substantially improved physicochemical and pharmacokinetic properties compared with SLL-039, with increases of over 20-fold in aqueous solubility and approximately 40-fold in oral bioavailability in rats.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01082.1H and 13C NMR spectra for all final compounds synthesized; HPLC spectra for SLL-1206; methods for the GTPγS binding assay, hot plate test, and abdominal constriction test; analytical method and pharmacokinetic data for SLL-1206 and SLL-039 (PDF)Molecular formula strings data (CSV)PDB data of the SLL-1206–κOR complex (PDB)This article has not yet been cited by other publications.

chemistry, medicinal